Literature DB >> 12654702

Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus.

Alexander J O'Neill, Ian Chopra.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12654702      PMCID： PMC152534          DOI： 10.1128/AAC.47.4.1484-1485.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany.

Authors:  G Bierbaum; K Fuchs; W Lenz; C Szekat; H G Sahl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

2.  Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area.

Authors:  R Geisel; F J Schmitz; L Thomas; G Berns; O Zetsche; B Ulrich; A C Fluit; H Labischinsky; W Witte
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

Review 3.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes.

Authors:  Keith Miller; Alexander John O'Neill; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

5.  Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

Authors:  A J O'Neill; J H Cove; I Chopra
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

Review 6.  Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50.

Authors:  Matthew B Avison; Peter M Bennett; Robin A Howe; Timothy R Walsh
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

7.  An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus.

Authors:  Franziska Schaaff; Andrea Reipert; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

9.  A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.

Authors:  S Boyle-Vavra; H Labischinski; C C Ebert; K Ehlert; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.

Authors:  Alexander J O'Neill; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790
View more
  3 in total

1.  Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.

Authors:  Hiep N'Guyen Trong; Anne-Laure Prunier; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 2.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

3.  From the wound to the bench: exoproteome interplay between wound-colonizing Staphylococcus aureus strains and co-existing bacteria.

Authors:  Andrea N García-Pérez; Anne de Jong; Sabryna Junker; Dörte Becher; Monika A Chlebowicz; José C Duipmans; Marcel F Jonkman; Jan Maarten van Dijl
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.